Cancer-testis (CT) antigens are potential targets for cancer immunotherapy because of their restricted expression in immune-privileged germ cells and various malignancies. Current application of CT-based immunotherapy has been focused on CT expression-rich tumors such as melanoma and lung cancers. In this study, we surveyed CT expression using the Cancer Genome Atlas (TCGA) datasets for ten common cancer types. We show that, CT expression is specific and enriched within certain cancer molecular subtypes. For example, HORMAD1, CXorf61, ACTL8 and PRAME are highly enriched in the basal subtype of breast cancer; MAGE and CSAG are most frequently activated in the magnoid subtype of lung adenocarcinoma; and PRAME is highly upregulated in the ccB subtype of clear cell renal cell carcinoma. Analysis of CT gene expression and DNA methylation indicates that some CTs are regulated epigenetically while others are controlled primarily by tissue-and subtype-specific transcription factors. Our results suggest that although for some CTs expression is associated with patient outcome, not many are independent prognostic markers. Thus, CTs with shared expression pattern are heterogeneous molecules with distinct activation modes and functional properties in different cancers and cancer subtypes. These data suggest a cancer subtype-orientated application of CT antigen as biomarkers and immunotherapeutic targets.
Introduction
The cancer-testis (CT) antigens are characterized by their spontaneous immunogenicity and distinct expression patterns normally restricted to germ cells of the testis and placenta but frequently are activated in tumor cells (1, 2) . T cells and antibodies against CT proteins are detectable in cancer patients (3) (4) (5) (6) (7) , suggesting that the abnormal expression of CT antigens in tumors could induce adaptive immune response. More than one hundred CT antigen genes have been identified (8). Among these, CT-X genes form clusters on the X chromosome (e.g., MAGE, SSX, and SPANX gene families) and encode the most immunogenic CT proteins. Other CT genes are single-copy genes located on various autosomes.
The expression frequency of CT genes varies greatly in cancers. Some cancers, such as colon, renal carcinoma, and glioblastoma, are CT-poor, with detectable CT expression in fewer than 20% of tumors. CT-rich cancer types, such as lung carcinoma and melanoma, can have CT expression frequencies greater than 50%.
Within a cancer type, CT expression is heterogeneous in tumor cells and varies among different tumor grades. For example, higher frequency CT gene expression has been reported in more advanced stages of non-small cell lung cancer (9, 10) . In bladder cancer, the expression of the MAGE gene family is most frequently found in the invasive forms (11) , and the expression of NY-ESO-1 is correlated with higher nuclear grade (12) . Author Manuscript Published OnlineFirst on November 25, 2013; DOI: 10.1158/2326-6066.CIR- Whether the reactivation of the CT genes in cancers represents a causal or correlative event is not clear and is under active investigation. Clinicopathological analyses have linked CT expression frequently with worse prognosis and less frequently with improved outcome in different cancer types (13) (14) (15) (16) (17) ; however, the molecular and cellular function of CT antigens is not well understood. For example, MAGEA11 is proposed to act as an oncogene by inhibiting prolyl hydroxylase 2 (PHD2) which down regulates the tumor-promoting hypoxiainducible factor alpha (HIF1-α) in prostate cancer cells (18) (19) (20) , MAGEA4 in the same gene family is suggested to be a tumor repressor by inducing apoptosis in non-small cell lung cancer (21) (22) (23) .
Due to their limited expression in normal tissues and their wide distribution in tumors, CT antigens are promising targets for cancer immunotherapy. However, clinical trials based on strategies targeting two well-characterized CT antigens (MAGEA3 and NY-ESO-1) have shown limited success in cancer patients (24) .
Recently two parallel phase II studies, using heterologous prime-boost vaccination with rV-NY-ESO-1 and rF-NY-ESO-1, have reported promising clinical benefit for patients with melanoma and ovarian cancer that are at high risk for relapse (25) .
Moreover, adoptively transferred autologous T cells transduced with a T-cell receptor (TCR) directed against NY-ESO-1 have mediated tumor regression in patients with synovial cell sarcoma (26) . In this study, we performed a comprehensive survey of the expression of CT antigens in multiple human cancers from the Cancer Genome Atlas (TCGA) RNAseq datasets and identified multiple tumor subtype-specific CT antigens that can be further studied as potential biomarkers and targets for immunotherapy.
Materials and Methods

Molecular profiling datasets and data preprocessing
Level 3 RNAseq data (RNAseq RPKM or RNAseqV2 RSEM), level 3 Agilent microarray data, level 2 DNA methylation data (Infinium Human Methylation 450), and clinical data for multiple cancers were downloaded from the TCGA data portal (ref. 27 ; https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm ). For DNA methylation data, M values were calculated as the log2 ratio of methylated intensity over unmethylated intensity (28) . For RNAseq data, RSEM (RNA-Seq by Expectation Maximization) values were used for most analyses since they produced similar results as those from RPKM (reads per kilobase per million mapped reads) but providing more coverage on tumor samples. RPKM values were used only in the expression heatmaps (as in Figure 2 ) for comparing the expression levels between genes. The breast cancer dataset NKI-295 (29) was downloaded from http:/microarray-pubs.stanford.edu//wound_NKI/explore.htm.
Due to ambiguous reads mapping to sets of genes with nearly 100% identity, only one gene of each set was used as a mapping target in RNAseq expression calculation. They include: CTAG1B for CTAG1A and CTAG1B; MAGEA2 for MAGEA2 and MAGEA2B; MAGEA9B for MAGEA9 and MAGEA9B; XAGE1D for XAGE1A, XAGE1B, XAGE1C, XAGE1D; GAGE12F for GAGE12F, GAGE12G and GAGE12I; GAGE12D for GAGE12C, GAGE12D and GAGE12E; SPANXB2 for SPANXB1 and SPANXB2.
Compilation of CT gene list
A list of 240 CT genes was queried from the current CT database (8). A search of the expression database generated from twelve normal somatic tissues by the Illumina BodyMap project (GEO accession: GSE30611) further narrowed this list down to 129 genes that have restricted expression in germ cells except for the minor expression in the brain.
Identification of CT gene overexpression in cancers and cancer subtypes
We examined CT gene expression in 318 normal tissue samples collected from autologous sites of six types of tumors (see supplemental CT genes with a cancer subtype-specific expression pattern. Based on different samples sizes, the P value cutoffs were set to 1e-12, 1e-8, 1e-5, and 0.02 for the BRCA, KIRC, LUAD, and COAD dataset, respectively.
Determination of tumor molecular subtypes using consensus clustering
Cancer molecular subtypes were determined by consensus k-means clustering of gene expression data using either Agilent microarray data or RNAseq RSEM values. Results using data from these two platforms from the same tumor correspond well with each other. The top 5,000 variably expressed genes with the highest Median Absolute Deviation (MAD) values were used to perform consensus clustering using the GenePattern website at http://genepattern.broadinstitute.org.
The conditions used were k-means max 5 clusters with 500 rounds of resampling iterations. Validation of clustering results for known breast cancer and glioblastoma subtypes were performed using clustering analysis of genes from PAM50 (30) and the 840-gene list (31) , respectively (see supplemental Figure S1 ).
Cluster analysis and statistical analysis. Clustering analyses were performed using the Cluster and TreeView software (http://rana.lbl.gov/EisenSoftware.htm). ANOVA test was conducted in R (http://www.r-project.org). For survival analysis, patients were stratified using the "k-means" function from the R software to two expression groups (high-expresser and low-expresser). Kaplan-Meier plots were drawn using the "survival" package from the R software. Multivariate analysis was carried out in SPSS Statistics 22. 
Results
CT gene expression in human cancers
We compiled a set of 129 CT genes, which includes 82 CT-X and 47 non-X CT genes (see Methods and supplemental Table S1 ). RNAseq data on nearly 3,500 tumor samples along with 318 normal tissues were obtained from the TCGA data repository, comprising ten cancer types including breast invasive carcinoma, lung adenocarcinoma, lung squamous carcinoma, colon adenocarcinoma, ovarian serous adenocarcinoma, clear cell renal cell carcinoma (ccRCC), head and neck squamous carcinoma, endometrial carcinoma, skin cutaneous melanoma, and glioblastoma (see supplemental Table S2 ). For RNAseq data, RSEM values were utilized for most analyses since these generated similar results as those from RPKM but with greater data coverage for tumor samples (32) . RPKM values were used only in expression heatmaps for comparing expression levels between genes.
To identify CT genes with restricted expression in tumors we first examined CT gene expression in all normal tissue samples collected from autologous sites of six types of tumors (see supplemental Table S2 ) and set a baseline for each CT gene as the median normal expression level plus 3 times standard deviation (see Methods).
Tumors with expression above the baseline for a particular CT gene were used for further analysis. Table S3 .
Enriched expression of CT genes in molecular subtypes of cancers
Since CT genes are often not prevalently overexpressed in cancers, and cancers are known to be intrinsically heterogeneous, we examined if CT genes are activated within particular cancer subtypes. To this end, we defined molecular subtypes of all ten cancers included in this study by consensus clustering of gene expression using the RNAseq RSEM values (see Methods). As expected, our analysis identified known molecular subtypes for breast, lung, and brain tumors (supplemental Figure S1 ). For example, our analysis separated breast cancers into luminal A/B, HER2-enriched, and basal subtypes (33) , glioblastomas into proneural, neural, classical, and mesenchymal subtypes (31) , and lung adenocarcinomas into bronchioid, magnoid, and squamoid subtypes (34 subtype named ccAB which has a gene expression pattern between those of the ccA and ccB classes (35, 36) . Many of these molecular subtypes are known to have prognostic value, which we confirmed in lung, kidney, and endometrial cancers (supplemental Figure S1 ), but not in breast cancer where basal subtype was a wellknown poor prognosis group (data not shown).
We next used the ANOVA test to identify CT gene expression enriched within cancer subtypes (see Methods). In breast cancer, we confirmed that CXorf61 and HORMAD1 were specific for the basal subtype and PLAC1 for the non-basal subtype (37, 38) . We also identified additional subtype-specific genes such as ACTL8 and PRAME for the basal subtype and POTEC for the non-basal subtype (Figure 2A, supplemental Table S4 ). In lung adenocarcinomas, a set of MAGE genes are most frequently overexpressed in the magnoid subtype and least expressed in the bronchioid subtype ( Figure 2C left panel) . Similarly, SEMG1 overexpression is enriched in the colon cancer COAD-1 subtype, SPACA3 is enriched in the COAD-2, -3 subtypes, and PRAME is enriched in the ccB subtype of ccRCC ( Figure 2D-E) . We validated our findings using external microarray gene expression datasets available for breast cancer and lung adenocarcinomas 34, 39) . This confirmed that basal breast cancers have higher expression of CXorf61, PRAME, ACTL8, and MAGEA3 ( Figure 2B ) and the expression of 
probes covering the entire gene structure and the 3 kb upstream promoter region for each of the 35 CT genes listed in Figure 3 .
The negative correlations between CT gene methylation and expression across cancer types are estimated and shown in Figure 4A , reporting the least median
Pearson correlation coefficient from all Met450 probes for one CT gene in eight tumors (see Methods and supplemental Table S5 ). This analysis confirmed that the transcription of the CT-X genes (e.g. MAGEs, CXorf61) is regulated primarily by promoter DNA methylation (45) . On the other hand, non-X CT gene expression correlated less well with DNA methylation except for PRAME and CTCFL. A detailed analysis of the CXorf61 gene expression and DNA methylation in breast cancers confirmed that it is more hypomethylated and highly expressed in basal tumors (Fig.4B left) . However, there are non-basal breast tumors that were equally methylated yet with less expression, indicating that there are other subtype-specific mechanisms inhibiting CXorf61 expression in non-basal tumors. There is a correlation between CXorf61 gene expression and DNA methylation in lung squamous carcinomas, even though it is not expressed in a subtype-specific manner.
Similarly, PRAME expression and DNA methylation are correlated in both breast cancer and lung squamous carcinomas, with better subtype-specificity in lung (Fig.4B right) . Thus, activation of CT genes which are enriched in certain cancer subtypes is likely to be controlled by both DNA methylation and other subtype-specific mechanisms.
Prognostic value of CT genes in ccRCC
Correlations between CT expression and cancer prognosis have been reported in various studies (46, 47) . In our analysis, we examined all 129 CT genes for their prognostic values with TCGA data by univariate Cox proportional hazard regression test in eight cancers using the same sample size of 200 randomly selected samples. This analysis revealed that approximately 15% of CT genes are potentially prognostic in ccRCC, a percentage much higher than those found in other cancer types ( Figure 5A and supplemental Table S6 ). Results from KaplanMeier survival analysis on the top three candidate prognostic genes are shown in Figure 5C , confirming that overexpression of SPANXC, C21orf99, and SSX1 are indicators of poor prognosis for ccRCC. When the same test was performed on all known genes, we found that more prognostic genes in ccRCC than in other cancers ( Figure 5A and 5B). Indeed, cluster analysis of ~3,000 prognostic genes found in ccRCC clearly identified two major types of prognostic genes, those highly expressed in the ccB subtype (poor prognostic genes) and those down-regulated in the ccB subtype (supplemental Figure S2) survival compared with the ccA and ccAB subtypes (supplemental Figure S1A) . A closer examination of CT gene expression associated with poor prognosis within the ccA, ccAB, and ccB subtypes also identified many CTs including the SPANXC and SSX1/2 genes with enriched expression in the ccB subtype ( Figure 5D ).
Therefore, a higher percentage of prognostic CTs seen in ccRCC are not unexpected. A previous study on conventional RCC identified a 259-gene prognostic gene expression signature, of which 45% of the genes overlap with our findings (data not shown) (48) .
ANOVA tests showed that the expression of the poor prognosis CTs (SPANXC, SSXs, C21orf99 and PRAME) is significantly associated with higher tumor grade/stage while the expression of the better prognosis CT (FATE1) is significantly associated with lower tumor grade/stage (supplemental Figure S2B ). This is in agreement with a previous report that the ccB subtype comprised higher grade tumors (36) . In the multivariate analysis with histological grade, pathological stage and metastatic status added as confounding variables, CT association with prognosis is either diminished or weakened even as the significance remains for some CTs such as SPANXC and SSX1. Similar results of prognostic feature were observed in other cancer types (supplemental Table S7 ). Therefore, a significant proportion of CT genes show prognostic values in ccRCC that can be attributed partly to their coincidental overexpression in the poor prognostic ccB subtype. As receptor (ER)-negative and basal breast cancer molecular subtypes (38) . Although in that study the analysis was limited to CT-X genes that were present on the arrays, it showed the possibility of identifying subsets of patients that could potentially benefit from CT-based immunotherapy approaches. This raises the possibility of using subtype-specific CT antigen information in clinical trial design within the context of several other factors such as the antigenicity of each CT, the specificity of gene expression, and the heterogeneity of CT expression within a tumor. A caveat to this approach is that in tumors heterogeneous for CT expression, antigen-negative tumor cells might escape from immune intervention.
Thus, finding additional options for CT-based immunotherapy would expand the reservoir for polyvalent vaccines in order to enhance immune response and reduce the chance of tumor cell escape from immunotherapy.
The control of CT expression was also examined in this study with the integration of the TCGA methylation data. As expected, CT-X genes cluster on the chromosome and usually are co-activated; for example, the MAGEA (2, 3, 6, 12) and CSAG (1, 2, 3 prognostic CT genes in ccRCC subtypes. Heatmap was generated using cluster and TreeView software after medium removal using RNAseq RSEM values. 
